Health
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.
About this update from Abbvie Inc.
[{"type":"text","content":"- Nine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluronic acid-based fillers and an innovative filler with biostimulatory properties- Pooled Phase 3 efficacy, safety and patient satisfaction data for TrenibotulinumtoxinE, a first-in-class botulinum neurotoxin serotype E that delivers rapid results with a short-duration of effect- Results from two Phase 4 studies of OnabotulinumtoxinA for Upper Facial Lines point to the benefit of long-term use and patient satisfaction with achieving natural outcomes. ","length":665,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Jan. 28, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.","length":546,"tagName":"p"},{"type":"text","content":""Allergan Aesthetics is driving the future of aesthetic medicine through a focus on scientifically driven innovation," said John Maltman, vice president, global aesthetics medical affairs, Allergan Aesthetics. "At IMCAS 2026, we're unveiling breakthrough new research that addresses patient concerns and offers health care providers new insight to on-market and emerging treatment options across neurotoxin, biostimulatory and HA filler modalities. These findings reinforce our commitment to delivering fully personalized, natural-looking outcomes using the Allergan Aesthetics facial injectable portfolio in the hands of skilled and trained clinicians."","length":678,"tagName":"p"},{"type":"text","content":"Poster Presentations","length":20,"tagName":"p"},{"type":"text","content":"Allergan Aesthetics will showcase data across its facial injectable portfolio and pipeline through a series of posters at IMCAS 2026 underscoring its leadership in evidence-based facial aesthetics.","length":197,"tagName":"p"},{"type":"tex...